Since 2011, we have leveraged our research platform, including expertise in molecular targeting and world-class drug design capabilities, to rapidly and reproducibly translate science into a broad pipeline of precision therapies. Applying an approach that is both precise and agile, we create medicines that selectively target genetic drivers, with the goal of staying one step ahead across stages of disease. The archived webcast will be available on Blueprint Medicines' website approximately two hours after the conference call and will be available for 30 days following the call.īlueprint Medicines is a global precision therapy company that invents life-changing therapies for people with cancer and blood disorders. A webcast of the call will also be available under "Events and Presentations" in the Investors & Media section of the Blueprint Medicines website at. To access the live conference call, please dial 84 (domestic) or 92 (international), and refer to conference ID 286085. The opinions expressed in this article are those of the writer, subject to the Publishing Guidelines. On the date of publication, Jeremy Flint held no positions in the securities mentioned. Although costly research caused more significant cash outflows in recent periods, the firm has sufficient runway to continue operations and ride the AI wave as they engineer healthcare’s future. More appealing to investors, though, is the relatively low stock price compared to peers in AI-enabled biotech spaces. The company’s extensive pipeline offers many AI-assisted opportunities for biotech investors. When therapeutic research is a complex game of identifying which compounds do as intended and what outcomes are merely byproducts, understanding single-cell outcomes is critical to drug discovery. In essence, the firm’s approach lets researchers dive into specific molecules that will benefit individual patients most. Exscientia was the first to bring an AI-designed molecule to clinical testing and recently began evaluating another AI-enhanced therapeutic. Unlike Recusion, Exscientia aims to develop bespoke drug solutions for patients. Like Recursion, Exscientia (NYSE: EXAI ) uses AI in its approach to drug discovery. A relatively new tool in the oncology kit, the partnership opens new vistas for cancer research and puts Blueprint at the forefront of biotech firms leveraging AI in clinical research. This technique uses the body’s “cellular machinery” to identify and mark faulty or cancerous cells for clinical targeting. Instead, they’ll serve the global community’s vital and growing needs.Īvoiding much of the complex science talk, the partnership lets Blueprint use Proteovant’s novel approach to protein degradation research to support its cancer treatment goals. As cancer rates continually increase each year, innovative approaches to oncology research won’t just benefit investors. ![]() Blueprint, a therapeutic biotech firm focused on cancer and blood disorder treatment, partnered with Proteovant Therapeutics in 2022 to leverage the private company’s AI-enhanced platform. In some ways, Blueprint Medicines (NASDAQ: BPMC ) was ahead of its time regarding AI-integrated healthcare solutions. With our powerful dataset and NVIDIA’s accelerated computing capabilities, we intend to create groundbreaking foundation models in biology and chemistry at a scale unlike anything that has ever been released in the biological space.” Recursion CEO Chris Gibson summed up the partnership in a press release : “Our collaboration with NVIDIA represents two best-in-class companies coming together to help solve one of the world’s most difficult challenges, drug discovery. Nvidia recognized the potential opportunity in Recursion’s methods and invested accordingly. ![]() A snag, slowdown, or regulatory hurdle anywhere in the process can push cash-strapped companies underwater permanently. ![]() This technology turns AI loose on massive chemical and biological datasets to help other biotech companies accelerate their pipeline processes.ĭrug pipelines, a lengthy process from drug discovery to FDA approval, represent the functional lifeblood of most biotech companies. The firm’s core function centers around its Recursion Operating System. On Wednesday, the firm reported a hefty $50 million cash infusion from Nvidia to support efforts in developing AI models that speed up drug discovery. Recursion Pharma (NASDAQ: RXRX ) made waves this week.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |